Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00159653 |
To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.
Condition | Intervention | Phase |
---|---|---|
Glaucoma, Open-Angle Ocular Hypertension |
Drug: Xalacom Drug: Xalatan Drug: Timolol |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Xalacom Given In The Evening, Xalatan Given In The Evening, And Timolol Given In The Morning In Patients With Open Angle Glaucoma Or Ocular Hypertension. |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Study ID Numbers: | A6641027 |
Study First Received: | September 8, 2005 |
Last Updated: | September 5, 2007 |
ClinicalTrials.gov Identifier: | NCT00159653 |
Health Authority: | United States: Food and Drug Administration |
Glaucoma Eye Diseases Glaucoma, Open-Angle Vascular Diseases |
Timolol Latanoprost Hypertension Ocular Hypertension |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents Therapeutic Uses Physiological Effects of Drugs Adrenergic beta-Antagonists |
Adrenergic Antagonists Cardiovascular Diseases Cardiovascular Agents Anti-Arrhythmia Agents Antihypertensive Agents Pharmacologic Actions |